ViiV Healthcare announces label update for its long-acting HIV treatment, Cabenuva (cabotegravir, rilpivirine), to be initiated with or without an oral lead-in period

US FDA approval of updated label streamlines the initiation process for the first and only complete long-acting HIV treatment by allowing people to start directly with injections For media and investors

Related Keywords

United States ,Glasgow ,Glasgow City ,United Kingdom ,North Carolina ,Philadelphia ,Pennsylvania ,Middlesex ,United Kingdom General ,Washington ,Brentford ,Hounslow ,London ,City Of ,Lynn Baxter ,Kathleen Quinn ,Dan Smith ,Josh Williams ,Jeff Mclaughlin ,Sonya Ghobrial ,Mick Readey ,Audrey Abernathy ,Catherine Hartley ,Tim Foley ,James Dodwell ,Kostenloser Wertpapierhandel ,Nick Stone ,Glaxosmithkline ,Drug Administration ,Janssen Pharmaceutical Companies Of Johnson ,Company Annual Report On Form ,Pfizer Inc ,Viiv Healthcare ,Janssen Sciences Ireland Unlimited Company ,Shionogi Limited ,Janssen Pharmaceutical Companies ,Johnson ,North America ,Safety Information ,Drug Reaction ,Systemic Symptoms ,Injection Reactions ,Adverse Reactions ,Virologic Response Due ,Drug Interactions ,Torsade De Pointes ,Acting Properties ,Potential Associated Risks ,Prescribing Information ,Annual Report ,England Wales ,West Road ,Lviiv ,Healthcare ,Nnounces ,Label ,Update ,Song ,Acting ,Treatment ,Cabenuva ,Cabotegravir ,Rilpivirine ,Nitiated ,Without ,Mural ,Head ,Eriod ,